Literature DB >> 27300677

Recurrent Chronic Obstructive Pulmonary Disease Exacerbations after Endobronchial Valve Implantation Are Associated with the Presence of Pseudomonas aeruginosa.

Izabela Tuleta1, Carmen Pizarro, Ernst Molitor, Glen Kristiansen, Georg Nickenig, Dirk Skowasch.   

Abstract

BACKGROUND: Endoscopic lung volume reduction by means of endobronchial valve implantation is an established therapy in patients with severe emphysema. However, long-term complications such as chronic obstructive pulmonary disease (COPD) exacerbations are a limitation of this method.
OBJECTIVES: As the mechanisms underlying increased rates of COPD exacerbations are unknown, the aim of our study was to determine whether infectious or inflammatory factors may contribute to these events and to investingate the consequent need for valve explantation.
METHODS: Tissue surrounding explanted endobronchial Zephyr valves was examined by microbiological, histological and cytological methods. Additionally, we performed a microbiological analysis of tracheal aspirates before both valve implantation and valve explantation. Moreover, blood samples were collected for the analysis of inflammatory markers.
RESULTS: Endobronchial valves were explanted from 16 patients. Reasons for explantation were frequent postprocedural COPD exacerbations (group 1: 8 patients) or loss of clinical benefit (group 2: 8 patients). Compared to group 2, the microbiological examinations of valve lavage and tracheal aspirates from patients in group 1 showed a higher detection of Gram-negative bacteria. In particular, infection with Pseudomonas aeruginosa was more predominant in group 1, while no presence could be detected in group 2. Blood inflammatory markers tended to be slightly higher in group 1 than in group 2; however, without reaching statistical significance.
CONCLUSIONS: Increased rates of COPD exacerbations after endobronchial valve implantation are associated with the presence of P. aeruginosa. The finding warrants further investigation.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27300677     DOI: 10.1159/000446925

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  2 in total

Review 1.  Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.

Authors:  Arschang Valipour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  New bacterial growth in bronchial secretions after bronchoscopic valve implantation.

Authors:  Nilab Sarmand; Daniela Gompelmann; Konstantina Kontogianni; Markus Polke; Felix Jf Herth; Ralf Eberhardt
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.